No standing medical-countermeasures stockpile and surge-manufacturing strategy

The £1bn Pandemic Preparedness Strategy of 2025 funds PPE replenishment, some UK vaccine capacity at Moderna's Harwell site, and testing-chemical stockpiles. CLTR notes the plan lacks a comprehensive strategy for medical-countermeasure supply-chain resilience and offers no detailed reshoring analysis. No standing surge-manufacturing warm base exists, no UK equivalent of a permanent BARDA-style capacity, and no published cross-hazard national stockpile strategy with maintained, rotated reserves.

In 2020 the UK was exposed by global scrambles for PPE, reagents and vaccines. Ad hoc stockpiles degrade and surge manufacturing cannot be improvised. A warm-base capability is the difference between countermeasures in 100 days and countermeasures in twelve months.

A published national stockpile strategy with rotated, cross-hazard reserves, plus funded warm-base surge-manufacturing capacity and reshoring of critical medical inputs, explicitly tied to the 100 Days Mission.

// State-led: Instrument: government stockpile strategy plus DHSC-funded BARDA-style warm-base manufacturing; spending-review decisions outsiders cannot ship.

Warm-base surge manufacturing decides 100-day versus 12-month countermeasures, and the £1bn strategy already funds adjacent stockpiles with no dated trigger for the reshoring piece.